Responses
Clinical/translational cancer immunotherapy
Original research
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
